Indivior stock rises on strong Q2 2026 earnings and higher full-year guidance

Indivior stock is benefiting from robust Q2 2026 earnings and a raised full-year 2026 outlook, with Sublocade driving double-digit revenue growth and analysts seeing upside from current levels.

Indivior Pharmaceuticals Inc. stock (ISIN US45580R1068) is drawing fresh investor interest after the company delivered sharply higher earnings in the second quarter of 2026 and raised its full-year guidance, while the Nasdaq-listed shares most recently closed at 35.05 USD on September 1, 2026 according to market data from Yahoo Finance.

Q2 2026 earnings show strong profit and revenue growth

According to an analysis published by Yahoo Finance and data compiled from recent coverage of Indivior's latest results, the company reported adjusted earnings of 1.15 USD per share in the second quarter of 2026, compared with a consensus estimate of 0.92 USD per share, marking an earnings surprise of 0.23 USD per share or about 25 percent above expectations.

The same Q2 2026 overview shows that Indivior generated revenue of 343 million USD in the second quarter of 2026, up 13.6 percent year over year, demonstrating that the specialty pharmaceuticals group is maintaining double-digit top-line growth while expanding margins.

Full-year 2026 guidance lifted across key metrics

Market data and recent analyst summaries indicate that, following the Q2 2026 report, Indivior raised its full-year 2026 net revenue guidance to a range of 1.295 billion to 1.365 billion USD, compared with a previous range of 1.215 billion to 1.285 billion USD, implying a midpoint increase of 80 million USD for the year.

For its flagship long-acting opioid use disorder treatment Sublocade, the company now expects 2026 net revenues between 1.01 billion and 1.05 billion USD rather than the prior range of 950 million to 990 million USD, which at the midpoint signals around 20 percent year-over-year growth in this product line from 2025 to 2026.

Indivior has also increased its adjusted EBITDA outlook for 2026 to a range of 700 million to 740 million USD, compared with the previous guidance band of 620 million to 660 million USD, while keeping adjusted operating expenses steady at 430 million to 450 million USD, pointing to improved operating leverage as revenues rise.

Sublocade remains a key growth driver

Indivior's revenue performance in Q2 2026 continues to be driven largely by Sublocade, its long-acting buprenorphine-based injection for opioid use disorder, with recent figures attributing the bulk of the 13.6 percent year-over-year revenue increase to this product's growing adoption in the United States and other markets.

The raised 2026 Sublocade net revenue range of 1.01 billion to 1.05 billion USD, compared with the prior 950 million to 990 million USD, underscores management's confidence in sustained demand growth and the strategic importance of this therapy in Indivior's portfolio.

Stock price context and investor perspective

Indivior Pharmaceuticals Inc. is listed on Nasdaq under the ticker INDV, and according to recent Nasdaq price data the shares closed at 35.05 USD on September 1, 2026, with that level serving as a reference point for investors assessing the revised full-year 2026 guidance and Q2 2026 earnings surprise.

Analyst information shown on the same overview indicates an average price target of 49.00 USD with a current price of 35.05 USD as of the close on September 1, 2026, suggesting that, in aggregate, the covering analyst community still sees upside relative to the latest trading level.

Indivior stock key data

• Company: Indivior Pharmaceuticals Inc.
• ISIN: US45580R1068
• Ticker: INDV
• Trading venue: Nasdaq
• Price (as of September 1, 2026, 16:00): 35.05 USD
• Market capitalization: 4,200,000,000 USD (as of September 1, 2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: None